AALL1931: JZP458-201: An Open Label Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia ALL/Lymphoblastic Lymphoma LBL Following Hypersensitivity to E. coli-derived Asparaginases

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Lymphoblastic Leukemia
    Lymphoblastic Lymphoma
  • Age: Between 0 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Pediatric and adult patients with a diagnosis of acute lymphoblastic leukemia (ALL) or LBL(lymphoblastic leukemia). 2) Female subjects of childbearing potential (ie, fertile, following menarche) and male subjects who have female partners of childbearing potential must agree to use medically acceptable methods of contraception with their partners from Screening, throughout the study, and for 30 days after the last dose of RC-P. 3) Have 1 or more courses of E. coli-derived asparaginase (ie, to allow for at least 6 doses of RC-P) remaining in his/her treatment plan.

You may not be eligible for this study if the following are true:

  • 1) Have previously received asparaginase Erwinia chrysanthemi or RC-P. 2) Have relapsed ALL or LBL. 3) Female patients who are lactating and do not agree to stop breast-feeding.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.